Mobile health applications in kidney stone disease management: A reliable support for patients?

Cirillo, Luigi; Manfredi, Celeste; Barone, Biagio; Morgera, Vincenzo; Cacace, Gianluigi; Mastrangelo, F; Bello, Francesco Di; Arcaniolo, Davide; Spirito, Lorenzo; Crocetto, Felice; Rocca, Roberto La; Creta, Massimiliano; Calace, Francesco Paolo; Fusco, Giovanni Maria; Napolitano, Luigi

doi:10.4081/aiua.2023.11076

Cited by 6 publications

(6 citation statements)

References 20 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Modern times bring along the popularization of innovative, complex technology, making it possible for patients to benefit from their smartphones to gather information from reliable sources on symptoms, prophilaxy and treatment options, and, at the same time, to calculate risks associated with their condition [ 33 ]. Artificial intelligence models will definitely change the future of urinary stone treatment, potentially reducing the need for surgical treatments.…”

Section: Discussionmentioning

confidence: 99%

Mini-Perc for Renal Stones—A Single Center Experience and Literature Review

et al. 2023

View full text Add to dashboard Cite

Aim: The aim of this study was to analyze the outcomes of miniaturized nephrolithotomy (mini-perc) in the management of renal stones with a diameter smaller than 20 mm. Materials and Methods: We retrospectively reviewed the records of 102 patients who underwent mini-perc between March 2015 and March 2020 in our department. The primary objective was the stone-free rate, but we also analyzed the retreatment rate, complications, hospital stay, operative time and reduction in hemoglobin level. All these patients had this technique as their first-line treatment, in a prone position, using a 16 Fr sheath size. Data were compared to a series of patients from the literature, treated with conventional PCNL. Results: The patients had calculus limited to either a single calyx or just extending to the renal pelvis, and stone size was less than 20 mm in its maximal dimension. The intrarenal stone location was in the upper calyx in 7 cases, middle calyx in 20 cases and lower calyx in 46 cases, and there were 29 patients with renal pelvis stone. The male to female ratio was 1.5:1, and the median age was 48.4 years. The average stone size was 17.4 mm in diameter (ranging between 9 and 20 mm) and all cases underwent Ho-YaG laser lithotripsy, ballistic energy and combined ultrasonic and ballistic lithotripsy. At the end of the procedure, an antegrade double J stent was placed under fluoroscopy for a maximum of 2 weeks in 42 cases, while 9 cases needed a nephrostomy tube 12–14 F. A total of 51 cases were totally tubeless. Our median operative time was 61 min (ranging from 35 to 75 min). The median hospitalization stay was 3.8 days. The stone free rate was 90.1% after one procedure, only nine (8.8%) cases needed a “second look” flexible ureteroscopy, and the final stone-free rate was 98% (absence of detectable calculi on ultrasound, KUB or non-contrast CT scan). The overall complication rate was 6.86% (Clavien classification I—57.14%; II—28.5%; III—14.2%), while no Clavien IV or V complications were reported. No patient required a blood transfusion, and mean hemoglobin loss was 0.81 mg/dL. Overall, our results are better than similar data for conventional PCNL in the literature. Conclusions: The “mini-perc” technique is an effective procedure for the treatment of the renal lithiasis that is less or equal to 2 cm. The results demonstrated that this minimally invasive technique is associated with a higher stone-free rate and minimal complications.

show abstract

Section: Discussionmentioning

confidence: 99%

Mini-Perc for Renal Stones—A Single Center Experience and Literature Review

et al. 2023

View full text Add to dashboard Cite

show abstract

“…Indeed, while MHAs on PSA are aesthetically satisfying (mean score of 3.11), the engagement, the functionality, the information, the MARS total mean score and the subjective quality were all under the threshold of acceptability, respectively. These findings are consistent with previous reports on urological and non-urological fields (Fusco et al ., 2022; Cirillo et al ., 2023). For instance, Napolitano et al .…”

Section: Discussionmentioning

confidence: 99%

“…Additionally, the remote visiting has overcome the geographic, sociodemographic, and economic inequalities in health care access (Rabinowitz et al , 2021; Samadbeik et al , 2022). Similarly, to the rise of teleconsultations, new items to manage the disease were created and promoted on social media such as mobile health applications (MHAs) (Napolitano et al , 2022a; Al-Dboush et al , 2023; Cirillo et al ., 2023; Tabira and Ohwatashi, 2023). Several previous studies enlightened the role of MHAs in daily management of patients, from pill program planning to get medical information (Napolitano et al , 2022b; Cirillo et al ., 2023).…”

Section: Introductionmentioning

confidence: 99%

A mobile health application for prostate cancer antigen dosage: is it time to say goodbye to classic screening methods?

Di Bello,

di Mauro,

Fusco

et al. 2023

European Journal of Cancer Prevention

View full text Add to dashboard Cite

Objective To evaluate the quality of apps for prostate cancer antigen (PSA) dosage, available for downloading on the iOS and Android platforms, discussing the potential role of mobile health applications (MHAs) in update the screening protocol. Methods An observational cross-sectional descriptive study of all smartphone apps for PSA dosage was performed through the most used platforms (iOS and Android). On 10 February 2023, a total of 457 apps were found according to the search criteria. Mobile Application Rating Scale (MARS) was adopted to assess apps’ quality. Then, MARS items were analyzed through descriptive statistics and bivariate correlations between study variables with Pearson’s coefficient. Results Of all samples, 24 MHAs were included in the final analysis: 12% (n = 3) from the iTunes App Store and 88% (n = 21) from the Google Play Store. According to the MARS quality assessment, the mean values 2.61, 2.94, 3.11, 2.97, 2.94, and 2.63 were measured for the engagement, functionality, aesthetics, information, overall mean score, and subjective quality, respectively. Conclusion The MHAs for PSA were under the acceptability threshold and future improvements are required. Moreover, MHAs appropriately developed could play an active role in PSA screening campaign and adherence of follow-up regimens. Finally, the virtual instrument could both reduce the social divide of access to care for patients in rural areas and improve PCA detection, speeding up the active treatment.

show abstract

“…ED may also be an indication of cardiovascular disease, and there is a strong likelihood that MetS will predispose an individual to ED given these shared pathways [43]. The precise mechanisms underlying the effects of many drugs and medications, including benzodiazepines, β-blockers, clonidine, digoxin, ketoconazole, methyldopa, monoamine oxidase inhibitors, phenobarbital, phenytoin, selective serotonin reuptake inhibitors, spironolactone, thiazide diuretics, and tricyclic antidepressants, can lead to erectile dysfunction [44].…”

Section: The Physiology Of Erection and The Pathophysiology Of Erecti...mentioning

confidence: 99%

New developments in erectile dysfunction treatments: A role for regenerative medicine

FY Ashari,

Yufi AZ,

Cennikon P

2023

World J. Adv. Res. Rev.

View full text Add to dashboard Cite

Erectile dysfunction is a highly prevalent issue related to the sexual wellness of millions of men worldwide. While conventional therapies have been successful for many, there remains a significant subset of individuals who do not respond adequately or experience undesirable side effects. This article reviews the emerging field of regenerative medicine as a potential breakthrough in the management of ED. Regenerative therapies, especially platelet-rich plasma (PRP) therapy along with stem cell therapy, provide novel approaches to tackling the fundamental causes of ED. By harnessing the body's natural healing mechanisms, these treatments hold promise for restoring erectile function and improving patients' quality of life. This review explores the mechanisms of action, benefits, and current research findings related to regenerative therapies for ED, emphasizing their potential to revolutionize the treatment landscape for this prevalent condition. As ongoing research continues to shed light on their safety and efficacy, regenerative therapies may pave the way for a brighter future in the management of erectile dysfunction.

show abstract

Mobile health applications in kidney stone disease management: A reliable support for patients?

Cited by 6 publications

References 20 publications

Mini-Perc for Renal Stones—A Single Center Experience and Literature Review

Mini-Perc for Renal Stones—A Single Center Experience and Literature Review

A mobile health application for prostate cancer antigen dosage: is it time to say goodbye to classic screening methods?

New developments in erectile dysfunction treatments: A role for regenerative medicine

Contact Info

Product

Resources

About